Tutkijat / Kuopio  | Airaksinen, O(lavi) |
| Alhava, E. |
| Alhonen, L. |
| Atalay, M(ustafa) |
| Cederberg, H. |
| Dunkel, L(eo) |
| Eskelinen, M(atti) |
| Giniatullin, R. |
| Gröhn, O(lli) |
| Harno, K. |
| Hartikainen, J(aana). |
| Hartikainen, J(uha). |
| Harvima, I. |
| Hiltunen, M(ikko) |
| Jääskeläinen, J(uha) E. |
| Jäkälä, P(ekka) |
| Jänne, J. |
| Jantunen, E(sa) |
| Järvinen, R. |
| Julkunen, P. |
| Kaikkonen, M(inna) U. |
| Kauhanen, J(ussi) |
| Kivipelto, M(iia) |
| Koistinaho, M. |
| Koivisto, T(imo) |
| Kokki, H. |
| Könönen, M. |
| Kosma, V(eli)-M(atti) |
| Kröger, H. |
| Kurl, S(udhir) |
| Kuusisto, J(ohanna) |
| Laakso, M(arkku) |
| Lakka, T(imo) A. |
| Lapinlampi, N(iina) |
| Laukkanen, J(ari) (UEF/KSSHP) |
| Levonen, A(nna)-L(iisa) |
| Lindgren, A(ntti) E. |
| Löppönen, H(eikki) |
| Mannermaa, A. |
| Manninen, H. |
| Mecklin, J(ukka)-P(ekka) |
| Moilanen, L(eena) |
| Mönkkönen, J. |
| Mykkänen, H. |
| Nuutinen, J. |
| Paajanen, H. |
| Paananen, J. |
| Palvimo, J.J. |
| Pelkonen, J(ukka) |
| Pihlajamäki, J(ussi) |
| Pihlajamäki, M. |
| Pitkänen, A(sla) |
| Punnonen, K. |
| Raatikainen K |
| Rauramaa, R. |
| Rissanen, T.T. |
| Roine, R(isto) P. |
| Ryynänen, O.P. |
| Saarikoski, S. |
| Schwab, U(rsula) |
| Sivenius, J. |
| Soininen, H(ilkka) |
| Soininen, P(asi) |
| Sorri, I. |
| Stancakova, A(lena) |
| Sulkava, R. |
| Sund, R(eijo) |
| Tammi, M. |
| Tanila, H(eikki) |
| Tiihonen, J(ari) |
| Uusaro, A. |
| Uusitupa, M. |
| Vanninen, R. |
| Vaskilampi, T. |
| Viinamäki, H(eimo) |
| Virtanen, M(arianna) |
| Voutilainen, R(aimo) |
| Voutilainen, S(ari) |
| Wahlfors, J. |
| Wirth, T. |
| Wong, G. |
| Ylä-Herttuala, S(eppo) |
Scholar Chart >>
|
»My Articles
»Latest Feeds
»Popular Feeds |
| | Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy. | Rissanen, T.T. | 405 days | save |  |  | |
| Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. | Rissanen, T.T. | 511 days | save | | | |
| Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. | Rissanen, T.T. | 597 days | save | | | |
| Conditional power analysis of the DEBUT trial - Authors' reply. | Rissanen, T.T. | 610 days | save | | | |
| Outcomes of lipid control in secondary prevention of coronary artery disease in Finland: A 24-month follow-up after acute coronary syndrome. | Rissanen, T.T. | 634 days | save | | | |
| CONTEMPORARY RADIATION DOSES IN INTERVENTIONAL CARDIOLOGY: A NATIONWIDE STUDY OF PATIENT SKIN DOSES IN FINLAND. | Rissanen, T.T. | 679 days | save | | | |
| Wrist band photoplethysmography in detection of individual pulses in atrial fibrillation and algorithm-based detection of atrial fibrillation. | Rissanen, T.T. | 775 days | save | | | |
| Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. | Rissanen, T.T. | 854 days | save | | | |
| Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. | Rissanen, T.T. | 860 days | save | | | |
| CONTEMPORARY RADIATION DOSES IN INTERVENTIONAL CARDIOLOGY: A NATIONWIDE STUDY OF PATIENT DOSES IN FINLAND. | Rissanen, T.T. | 922 days | save | | | |
| Effectiveness of the Chest Strap Electrocardiogram to Detect Atrial Fibrillation. | Rissanen, T.T. | 952 days | save | | | |
| Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: An all-comers registry study. | Rissanen, T.T. | 1089 days | save | | | |
| Outcome of Cardiac Sarcoidosis Presenting With High-Grade Atrioventricular Block. | Rissanen, T.T. | 1095 days | save | | | |
| Ventricular fibrillation recorded and analysed within an area the size of a mobile phone: could it enable cardiac arrest recognition? | Rissanen, T.T. | 1129 days | save | | | |
| Outcomes of Secondary Prevention among Coronary Heart Disease Patients in a High-Risk Region in Finland. | Rissanen, T.T. | 1292 days | save | | | |
| Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. | Rissanen, T.T. | 1502 days | save | | | |
| Percutaneous Coronary Intervention of Complex Calcified Lesions With Drug-Coated Balloon After Rotational Atherectomy. | Rissanen, T.T. | 1734 days | save | | | |
| Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety study. | Rissanen, T.T. | 1836 days | save | | | |
| AdVEGF-B186 and AdVEGF-DΔNΔC induce angiogenesis and increase perfusion in porcine myocardium. | Rissanen, T.T. | 1990 days | save | | | |
| Ultrasound Screening of Men with Coronary Artery Disease for Abdominal Aortic Aneurysms: A Prospective Dual Center Study. | Rissanen, T.T. | 2063 days | save | | | |
| The feasibility of recognizing the heart rhythm with an automated external defibrillator from an area the size of a mobile phone. | Rissanen, T.T. | 2564 days | save | | | |
| Ultrasound imaging with bolus delivered contrast agent for the detection of angiogenesis and blood flow irregularities. | Rissanen, T.T. | 2565 days | save | | | |
| HIF-1α and HIF-2α induce angiogenesis and improve muscle energy recovery. | Rissanen, T.T. | 2601 days | save | | | |
| The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs. | Rissanen, T.T. | 2975 days | save | | | |
| Baculovirus-mediated VEGF-D(?N?C) Gene Transfer Induces Angiogenesis In Rabbit Skeletal Muscle. | Rissanen, T.T. | 3603 days | save | | | |
| Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. | Rissanen, T.T. | 3791 days | save | | | |
| Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. | Rissanen, T.T. | 3818 days | save | | | |
| Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy. | Rissanen, T.T. | 3974 days | save | | | |
| The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice. | Rissanen, T.T. | 4344 days | save | | | |
| VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. | Rissanen, T.T. | 4575 days | save | | | |
| Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1- and Neuropilin Receptor-1-Dependent Mechanisms. | Rissanen, T.T. | 4647 days | save | | | |
| Vascular Endothelial Growth Factor-A and Platelet-Derived Growth Factor-B Combination Gene Therapy Prolongs Angiogenic Effects via Recruitment of Interstitial Mononuclear Cells and Paracrine Effects Rather Than Improved Pericyte Coverage of Angiogeni | Rissanen, T.T. | 4770 days | save | | | |
| Therapeutic Angiogenesis with Placental Growth Factor Improves Exercise Tolerance of Ischemic Rabbit Hindlimbs. | Rissanen, T.T. | 4842 days | save | | | |
| Current Status of Cardiovascular Gene Therapy. | Rissanen, T.T. | 5276 days | save | | | |
| [In Process Citation] | Rissanen, T.T. | 5318 days | save | | | |
| Adenovirus-Mediated Gene Transfer of Human Vascular Endothelial Growth Factor-D Induces Transient Angiogenic Effects in Mouse Hind Limb Muscle. | Rissanen, T.T. | 5337 days | save | | | |
| Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. | Rissanen, T.T. | 5340 days | save | | | |
| Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. | Rissanen, T.T. | 5508 days | save | | | |
| Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart--gene therapy. | Rissanen, T.T. | 5508 days | save | | | |
| Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. | Rissanen, T.T. | 5508 days | save | | | |
| Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. | Rissanen, T.T. | 5508 days | save | | | |
| Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer. | Rissanen, T.T. | 5570 days | save | | | |
| | 
report | | | |
|
